#United States #Chicago #Cancer Immunotherapy #ProBio #CD3 Antibody

ProBio to Showcase Groundbreaking Antibody Platform at AACR 2025

ProBio, a prominent player in antibody discovery and development, is gearing up for a significant presentation at the upcoming 116th Annual Meeting of the American Association for Cancer Research (AACR), scheduled from April 25 to 30, 2025. This event, which takes place at the McCormick Place Convention Center in Chicago, Illinois, will serve as a platform for ProBio to reveal its latest advancements in immunotherapy.

Presentation Highlights

During the conference, ProBio will present compelling pre-clinical data that underscores the efficacy of its CD3 agonistic single-domain antibody platform (sdAb/VHH). This innovative framework is essential for developing next-generation T cell engager (TCE) bispecific and multi-specific antibodies, which are rapidly gaining traction in the field of cancer treatment. Allen Guo, ProBio's CEO, expressed his anticipation for the presentation, emphasizing the platform's design flexibility and safety profile, crucial for creating effective treatments for various cancers.

Guo stated, “We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody. This platform offers a unique combination of potency, design flexibility, and a favorable safety profile, making it an ideal foundation for developing highly effective bispecific and multi-specific antibodies for various cancers.”

Addressing Limitations in Immuno-Oncology

ProBio's contribution to the T cell engager landscape is poised to address several inherent limitations of traditional CD3 binders. These challenges include safety concerns, potency limitations, and design difficulties in deploying effective immunotherapies. The proprietary single-domain antibody technology employed by ProBio allows for the customization and scalability of these important therapeutic agents. The research indicates increased efficacy in tumor-killing capabilities while maintaining improved safety profiles.

Institutional backing in the form of integrated Contract Development and Manufacturing Organization (CDMO) capabilities further positions ProBio to lead in the antibody development space. This comprehensive model merges discovery with scalable Chemistry, Manufacturing, and Controls (CMC) processes, enabling swift transitions from concept to clinical applications, ultimately reducing both development risks and timelines.

Expert Insights and Future Directions

Dr. Yu Liang, the Head of Discovery at ProBio, highlighted the necessity for innovation in immune-oncology. He remarked, “Our CD3 single-domain antibody platform represents the innovation needed to address some of the most pressing challenges in immune-oncology – delivering potent, modular, and clinically translatable solutions.” By combining extensive scientific insights with a robust development framework, ProBio aims to hasten the introduction of transformative immunotherapies into clinical practice.

The firm is committed to fostering international collaborations to advance innovative solutions for treating various forms of tumors, both solid and liquid. ProBio’s platform not only supports its initiatives but also provides substantial advantages for biotech and pharmaceutical partners looking to optimize their pathways to drug development.

About ProBio

As a leader in the field, ProBio specializes in facilitating collaborations that enhance the development and manufacturing of cutting-edge therapies. Adopting a risk-sharing model, ProBio offers a flexible framework for licensing and co-developing molecules, empowering partners to navigate the intricacies of disease management with innovative therapeutic methods. For more information about ProBio’s initiatives and their impact on cancer treatment, please visit www.probiocdmo.com.

Conclusion

In summary, ProBio’s presentation at AACR 2025 is set to highlight pivotal advancements in antibody technology, pushing the boundaries of cancer treatment. Its ongoing commitment to innovation and collaboration positions it at the forefront of therapeutic development, promising to enhance patient outcomes in the evolving landscape of cancer immunotherapy.